MoneyWorks4Me

Sandu Pharmaceutical - Quaterly Results

06 May 2026 Evaluate
The Revenue for the quarter ended  March 2026 of Rs. 168.53 millions grew by 19.79 % from Rs. 140.69 millions.The company reported a drastic decline of -86.85% in the quarter ended March 2026 to Rs. 0.43  millions from Rs. 3.27 millions  .OP of the company witnessed a marginal growth to 9.38 millions from 5.17 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202603 202503 % Var 202603 202503 % Var 202603 202503 % Var
Sales 168.53 140.69 19.79 699.34 671.92 4.08 699.34 671.92 4.08
Other Income 3.65 0.69 428.99 4.44 1.68 164.29 4.44 1.68 164.29
PBIDT 9.38 5.17 81.43 34.43 29.30 17.51 34.43 29.30 17.51
Interest 0.26 0.26 0.00 1.12 1.03 8.74 1.12 1.03 8.74
PBDT 9.12 4.91 85.74 33.31 28.27 17.83 33.31 28.27 17.83
Depreciation 1.65 1.48 11.49 6.77 6.71 0.89 6.77 6.71 0.89
PBT 7.47 3.43 117.78 26.54 21.56 23.10 26.54 21.56 23.10
TAX 7.04 0.16 4300.00 8.89 6.07 46.46 8.89 6.07 46.46
Deferred Tax 1.64 -0.58 -382.76 1.04 0.18 477.78 1.04 0.18 477.78
PAT 0.43 3.27 -86.85 17.65 15.49 13.94 17.65 15.49 13.94
Equity 96.61 96.61 0.00 96.61 96.61 0.00 96.61 96.61 0.00
PBIDTM(%) 5.57 3.67 51.46 4.92 4.36 12.90 4.92 4.36 12.90
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..